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2Abstract
Background: The association between asthma and type 1 diabetes, two chronic, immune-
mediated diseases, has been of longstanding interest, but the evidence is still conflicting. We
examined this association in a large, nationwide case-cohort study among Finnish children
using a novel statistical approach.
Methods: Among the initial cohort of all children born between 1.1.1981–31.12.2008, those
who were diagnosed with asthma (n = 81 473) or type 1 diabetes (n = 9541) up to age 16
years by the end of 2009 were identified from the Central Drug Register maintained by the
Social Insurance Institution of Finland. A 10% random sample from each initial birth year
cohort was selected as a reference cohort (n = 171 138). The association between asthma and
type 1 diabetes was studied using a multistate modeling approach to estimate transition rates
between healthy and disease states since birth. Hazard ratios (HRs) with 95% confidence
intervals (CIs) were calculated to represent the change in the transition rate between the
disease states.
Results: After adjusting for sex and birth decade, prior diagnosis of asthma increased the risk
of subsequent type 1 diabetes by 41% (95% CI: 1.28, 1.54), while prior diagnosis of type 1
diabetes decreased the risk of subsequent asthma by 18% (95% CI: 0.69, 0.98).
Conclusions: The findings of the present study imply that the association between the
diseases is more complex than previously thought, and its direction depends on the sequential
appearance of the diseases.
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3Key messages:
· This study used nationwide registers to design the case-cohort setting and a multistate
modelling approach to analyze the association between asthma and type 1 diabetes in
childhood and adolescence.
· Children with prior diagnosed asthma were at increased risk of subsequent type 1
diabetes.
· Children with prior diagnosed type 1 diabetes were at decreased risk of subsequent
asthma.
· These findings were not explained by age at diagnosis, birth decade, sex, maternal
asthma/diabetes or birth-related factors
· The findings imply that the association between asthma and type 1 diabetes is
complex, and the direction of the association may depend on which disease appears
first.
4Asthma is among the leading chronic diseases in children in many developed countries, and
incidence of childhood type 1 diabetes has increased in several parts of the world. (1, 2) The
pathogenesis of type 1 diabetes has been related to T-cell-mediated, primarily T helper type 1
(Th1), autoimmune responses, whereas Th2-type responses are considered to play a major
role in the pathogenesis of asthma and allergic diseases. The paradigm of reciprocal counter-
regulation of Th1 and Th2 cells predicts that asthma and type 1 diabetes would occur in
mutually exclusive populations of individuals, and several studies have investigated an
inverse association between asthma and type 1 diabetes.
Pooled results from a meta-analysis published in 2003 supports the inverse association
(OR= 0.82; 95% CI: 0.68, 0.99) (3), although findings from individual studies included in the
meta-analysis and published thereafter are inconsistent; inverse, direct and null associations
have all been reported. (3, 4) These inconsistencies imply that the early version of the so-
called Th1/Th2 paradigm may be an oversimplification (4), but also methodological issues
may have contributed to the contradictory findings. Thus, the association between asthma and
type 1 diabetes needs clarification with methods allowing assessment of the potential
complexity of the association.
The aim of the present study was to clarify the association between asthma and type 1
diabetes in childhood and adolescence in a large, nationwide case-cohort study using a novel
approach. With multistate modeling, we estimated transition rates between healthy and
disease states, asthma and type 1 diabetes, since birth.
METHODS
Data sources
Data for the present case-cohort study were obtained from nationwide Finnish health
registers, which were merged by deterministic linkage with unique personal identity codes. (5,
56) Information on asthma, type 1 diabetes, and the reference cohort as well as anti-asthmatic
drug and insulin purchases was obtained from the Central Drug Register maintained by the
Social Insurance Institution (SII). Since 1964, patients with certain severe and chronic
diseases, such as asthma or type 1 diabetes, have been entitled to special reimbursements for
the cost of drugs needed in the treatment of the disease, regardless of their socioeconomic
status, residence or place of treatment. To be eligible for this special reimbursement, the
diagnosis has to be verified by a specialist in pediatrics and/or a respective field, and a
certificate of the diagnosis is required. Further, in the case of childhood asthma, a long-lasting
drug treatment is required. For example, the use of antiasthmatic drugs during a few months
in the pollen season does not fulfill this requirement. Finally, a clinical specialist at the SII
reviews all special reimbursement applications and certificates. The administrative process for
decision-making by the SII takes only a couple of weeks. Thus, the date of the entitlement
decision obtained from the Central Drug Register's Special Reimbursement database was used
as a proxy for the date of diagnosis.
To further verify the case definitions, we used information on antiasthmatic drug and
insulin purchases obtained from the Central Drug Register's Purchase database. In Finland, all
these drugs are prescription-only medicines, and since 1994 they have been reimbursed by the
National Health Insurance scheme, and recoded to the Central Drug Register. However, drugs
used in hospital settings are not recoded to this register. Information included in the study was
the date of purchase and the Anatomical Therapeutic Chemical (ATC) code of the drug.
Information on potential confounding factors, like maternal age at delivery, socioeconomic
status (based on occupation or the highest education level if the occupation was missing, and
categorized as "upper white-collar workers", "lower white-collar workers", "blue-collar
workers" and "others" including farmers, entrepreneurs, retired, unemployed, students and
housewives), smoking during pregnancy (no/yes), number of previous deliveries (0, 1, ≥2)
6and mode of delivery (vaginal delivery/caesarean section) was derived from the Finnish
Medical Birth Register, which has been collected since 1987 and is currently maintained by
the National Institute for Health and Welfare. Information on maternal socioeconomic status
has been available since 1991. Information on maternal asthma and diabetes was based on
special reimbursements granted from the Central Drug Register. Information on the child's
sex and year of birth, further categorized as birth decade (1980s, 1990s, 2000s), was available
in both registers.
Study population
From the initial cohort of all children born between January 1, 1981, to December 31, 2008,
we identified all those who had received a special reimbursement for the costs of insulin or
antiasthmatic drug purchases before age 16 years by the end of year 2009 as type 1 diabetes
(n = 9541) and asthma cases (n = 81 473), respectively. A 10% random sample from each
initial birth year cohort (1981–2008) was selected as a reference cohort (n = 171 138).
As the above definitions could be open to false positive cases, we also conducted a
sensitivity analysis applying a stricter case definition. In type 1 diabetes, cases who had no
insulin (ATC code A10A) purchases after the diagnosis were excluded (n = 64, 0.7%). For a
strict asthma definition, cases who had a short duration of the special reimbursement (less
than 6 months) and/or no antiasthmatic drug purchases (inhaled corticosteroids, ATC code
R03BA; a fixed combination containing inhaled corticosteroids and either salmeterol or
formoterol, codes R03AK06 and R03AK06; and montelukast, code R03DC03) after the
diagnosis were excluded (n = 5197, 6.4%).
7Statistical analysis
The data were analyzed with a multistate modeling approach with transition times based on
the dates of diagnosis obtained from the Central Drug Register. The states were defined as
“healthy” (i.e. no type 1 diabetes or asthma), “asthma only”, “type 1 diabetes only” and “both
asthma and type 1 diabetes”. We modeled the transition rates between the states by a
piecewise exponential model for each transition with knots placed at 4, 8 and 12 years of age
allowing heterogeneity in the incidence of asthma and diabetes at different ages. The results
were not sensitive to the particular choice of knot positions. The piecewise exponential model
was chosen because the assumption of constant transition rates for such a long follow-up
period was considered unrealistic, and it is a conventional and incorporated feature in
available multistate models software. (7) Birth was taken as the time of origin without time
reset at a transition. The time scale was from birth up to age 16 years, death, or December 31,
2009, whichever came first.
Four transitions between states were therefore possible over the follow-up time for each
child. Our initial model included no covariates, and we estimated four piecewise transition
rates (rate 0–3.9, 4–7.9, 8–11.9 and 12–16 years) for the four transitions. Based on the raw
transition rates, we noted that the rates for a disease were modified similarly at different ages
by the appearance of the other disease, and we estimated a single hazard ratio to represent that
average change. Another hazard ratio parameter was estimated to represent the change in the
reverse time-order of the diseases. After this simplification of the model, we investigated the
effect of potential confounders known to be associated with the incidences of asthma and type
1 diabetes (maternal age, socioeconomic status, smoking, previous deliveries, mode of
delivery, asthma and diabetes, as well as the child's sex and birth decade). Among them, sex
and birth decade appeared to be the most important confounders. Thus, they were included in
the final model as main effects, assuming proportionality of rates, as we did not detect
8evidence of second-order interactions between age group, sex and birth decade. The final
multistate model is illustrated in Figure 1. The transition rates of the final model were
converted into transition-, sex- and birth decade-specific incidences to aid their interpretation
and to allow comparisons with previous evidence.
The model was fitted with maximum likelihood, and the standard errors of the parameter
estimates were derived from the observed information matrix. The case-cohort setting of the
data was taken into account by acknowledging the sampling probabilities in the derivation of
the likelihood expression via Bayesian inversion, as in the approach of Chen et al. (8) The
model was fitted with the NLMIXED procedure in SAS, version 9.4 (SAS Institute, Cary,
NC).
We conducted a series of analyses to examine sensitivity 1) to the case definition criteria
by using a strict definition; 2) to different approaches of handling missing values in the
confounding factors: missing values treated as a category of their own, excluding children
with missing values in at least one of the confounding variables, and multiple imputation; and
3) of associations and the effect of the order and age at diagnosis of the diseases using more
conventional but crude methods of analysis (9). As the results using a strict case definition did
not change substantially, only the results using the main case definition are presented.
Ethics committee approval
This study was approved by the National Data Protection Authority, the institutions keeping
the registers and the Institutional Review Board of the National Institute for Health and
Welfare.
9RESULTS
We identified 80 871 children with only asthma and 8939 children with only type 1 diabetes
and 602 with both diseases. Median follow-up time was 15.5 years, and 90% of the children
were followed-up for at least 3.8 years. Of the children with both diseases, 75.7% had asthma
diagnosed before type 1 diabetes, 20.9% had type 1 diabetes diagnosed before asthma, and
3.3% had both diseases diagnosed within the same month. Median age at diagnosis was 4.6
years (interquartile range, IQR 5.9) in asthma and 7.5 years (IQR 6.7) in type 1 diabetes. The
proportion of boys was 61.9% in children with only asthma, 54.4% in children with only type
1 diabetes and 62.5% in children with both asthma and type 1 diabetes, as well as 51.2% in
the reference cohort (Table 1). Maternal diabetes and asthma were more common in cases of
both diseases compared to the reference cohort. The frequency of children with asthma and
type 1 diabetes increased with age and from the 1980s, although in asthma the striking
increase seems to level off in children born in the 2000s (Figure 2). Annual, multistate model-
based and sex-, age group- and birth decade-specific incidences of type 1 diabetes and asthma
are presented in Supplementary Tables 1 and 2, available as Supplementary data at IJE online.
The observed transitions from healthy state (no asthma or type 1 diabetes) to disease state
(asthma or type 1 diabetes) and between disease states (from asthma to type 1 diabetes and
vice versa) presented in Table 2 show that type 1 diabetes developed more frequently in
children with asthma (0.6%) than in healthy children (0.4%), and asthma developed less
frequently in children with type 1 diabetes (1.7%) than in healthy children (2.7%). This
phenomenon remained similar when children with diseases diagnosed before age 4 years were
excluded: type 1 diabetes developed more frequently between ages 8 to 16 years in children
with asthma diagnosed between ages 4 to 7.9 years (0.4%) than in children with good health
for up to 8 years (0.3%). Further, asthma developed less frequently between ages 8 to 16
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years in children with type 1 diabetes diagnosed between ages 4 to 7.9 years (1.0%) than in
with good health for up to 8 years (1.3%).
The multistate model gave similar results: children with asthma were at increased risk of
subsequent type 1 diabetes (unadjusted HR= 1.45, 95% CI: 1.32, 1.60), while children with
type 1 diabetes were at decreased risk of subsequent asthma (unadjusted HR= 0.70, 95% CI:
0.59, 0.84) compared with children without asthma or type 1 diabetes, respectively. Results
from the final multistate model are presented in Figure 3. Adjustment for sex and birth decade
diminished the crude estimates slightly, but further adjustment for other potential confounding
factors did not change the estimates substantially (data not shown). Boys had a higher risk of
both asthma and type 1 diabetes compared with girls, and children born in the 1990s and
2000s had a higher risk of both asthma and type 1 diabetes compared with children born in
the 1980s (Figure 3).
The results were not sensitive to the particular missing data approach used (Supplementary
Table 3). In addition, the results from the sensitivity analyses underline the importance of
careful recognition of the sequential ordering and the age on the association between asthma
and type 1 diabetes, as the multistate model does (Supplementary Table 4).
DISCUSSION
In the present study, children with asthma had an increased risk of subsequent type 1 diabetes,
but children with type 1 diabetes had a decreased risk of subsequent asthma after adjustment
for putative confounding factors. Thus, the presence of asthma or type 1 diabetes modified the
incidence of type 1 diabetes and asthma respectively, compared with the incidence in children
without these diseases.
Previous studies assessing the association between asthma and type 1 diabetes have
reported conflicting findings. While a meta-analysis summarizing studies published in March
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2003 reported a slight inverse association between asthma and type 1 diabetes, (3) both direct
and null associations have been reported as well. (4, 10–12) Many of these previous studies
were of case-control design with relatively small sample sizes, and type 1 diabetes was
mainly used as the index disease. Further, whether an asthma diagnosis or symptoms were
present during the time before type 1 diabetes diagnosis was not clear in all studies. Only a
few studies have investigated an association between asthma and type 1 diabetes in a
prospective cohort design with inconsistent findings. (11–14)
Our finding that type 1 diabetes develops more often in asthmatic children compared with
non-asthmatic children is in line with two other cohort studies, (11, 14) and a birth cohort
study where early life wheezing (associated with asthma development) increased the risk of
appearance of autoantibodies (associated with type 1 diabetes development). (10) However,
our finding that asthma develops less often in type 1 diabetic children compared with healthy
children is in contrast to the findings by Hsiao et al. (12) and Kero et al. (13) This discrepancy
may be due to methodological differences between the studies. Kero et al. (13) did not
distinguish the sequential appearance of the diseases, and they followed up the children only
until 7 years of age. Findings from the study by Hsiao et al. (12) may be subject to
surveillance bias, which may occur when regular contacts or screenings after the diagnosis of
a chronic disease increase the likelihood of subsequent detection of another disease. In the
study by Hsiao et al. (12) the risk of asthma was increased in those type 1 diabetics who were
more than two times hospitalized or visited the emergency room because of type 1 diabetes,
while no association was observed in those type 1 diabetics with two or less hospitalizations
or emergency room visits compared with control children. As far as we know, no previous
studies exploring the sequential appearance of these diseases similarly to the present study
have been published.
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Major strengths of the present study were the size of the study, the particularly large
number of cases and prospectively collected information. The latter allowed us to establish
the temporal relationship of the diagnoses and minimize recall bias. However, we were not
able to verify the initial starting point of the disease process, which in both asthma and type 1
diabetes may be several months before the actual date of diagnosis. Further, challenges in the
diagnosis of asthma in small children increase the possibility that transient early wheezers
were included as asthma cases in the present study. (15) However, as the results did not
change substantially when analysis was restricted to children receiving the asthma diagnosis
after 4 years of age, or when a more strict case definition was applied, this misclassification is
probably not a major source of bias in our study. Further, as information on the exact
diagnosis codes was not complete for the whole study period, we cannot exclude the
possibility that some cases of type 2 diabetes may have been falsely classified as type 1
diabetics in our data. Although we were able to take into account several confounders,
information on some important environmental factors affecting the development of both
asthma and type 1 diabetes, like infections and nutritional factors, (16, 17) was not available.
Thus, residual confounding cannot be excluded. Our observation of an increased incidence of
type 1 diabetes after asthma diagnosis may be subject to surveillance bias, but as an opposite
was observed when the diseases occurred vice versa, we believe that the surveillance bias
does not fully explain our results. Further, the higher incidence of type 1 diabetes and lower
asthma prevalence in Finland compared to many other countries, and the fact that the study
includes asthmatics needing long-lasting drug treatment limits the generalizability of our
results.
The results of the present study support the view that the Th1/Th2 paradigm is likely an
oversimplification. In fact, far more complex immunological mechanisms, which explain that
asthma and type 1 diabetes may coexist, have been described: Th1-inflammation may
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suppress the development of atopy, and atopy may suppress the severity but not necessarily
the onset of autoimmunity (4) However, our findings do not fully support this immunological
model. This inconsistency may be due to the fact that asthma is not a single disease, but a
heterogeneous syndrome with different endotypes that do not all have Th2-dominant
mechanisms. (18)
The medication used in the treatment of asthma, mainly inhaled corticosteroids, may
potentially underpin the observed association. Although, the use of systemic corticosteroids is
known to induce insulin resistance and hyperglycemia, the role of inhaled corticosteroids in
glucose metabolism is still debated. (19) Thus, the role of corticosteroids in the development
of type 1 diabetes is potential, but uncertain. As far as we know, no human studies linking
insulin used in the treatment of type 1 diabetes and the development of asthma have been
published. Another explanation for the fewer asthma diagnoses after type 1 diabetes could be
that parents may not recognize their child's asthma-like symptoms or that the symptoms are
considered less relevant due to the burden of caring for a child with type 1 diabetes.
The present findings indicate that the association between type 1 diabetes and asthma is
complex, and further studies that also take into account the sequential appearance of the
diseases in prospective study settings and in different study populations are needed to confirm
or refute the findings. Further, the role of antiasthmatic drugs, particularly corticosteroids, in
the development of type 1 diabetes should be explored. In addition, studies assessing other
allergic diseases, biomarkers of atopy and Th-balance may further elucidate the coexistence of
allergic diseases and type 1 diabetes.
In conclusion, we observed that children with asthma had an increased risk of subsequent
type 1 diabetes, but children with type 1 diabetes had a decreased risk of subsequent asthma.
Before any clinical implications can be drawn from these findings, further studies in different
populations and on potential biological mechanisms are warranted.
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N of subjects 80 871 8 939 602 171 138
Male sex (%) 61.9 53.9 62.5 51.2
Child's birth decade (%)
  1980s 30.3 38.9 27.7 33.3
  1990s 50.2 47.1 61.3 36.5
  2000s 19.6 14.1 11.0 30.3
Maternal diabetes (%) 2.2 4.9 4.2 1.8
Maternal asthma (%) 14.4 6.0 15.0 5.4
Maternal age at deliverya (mean,
years)
28.9 29.3 29.3 29.3
Maternal socioeconomic status
at delivery (%)
  Upper white-collar worker 9.7 9.0 11.3 12.0
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  Lower white-collar worker 29.6 25.9 34.7 35.1
  Blue-collar worker 10.7 9.3 9.6 12.2
  Others 11.3 8.9 10.3 12.0


















  No 67.5 66.0 72.4 65.8
  Yes 11.4 6.7 8.5 9.2
  Missing information 21.1 27.3 19.1 25.0
Number of maternal previous
deliveries (%)
  0 33.2 30.6 31.4 31.3
  1 27.4 26.1 31.9 26.0
 ≥2 20.0 17.7 18.9 19.3
  Missing information 19.5 25.6 17.8 23.4
Mode of delivery (%)
  Vaginal delivery 65.3 61.7 64.0 64.5
  Caesarean section 15.5 12.9 18.1 12.3
  Missing information 19.3 25.5 17.9 23.2
a The Medical Birth Register data including maternal age at delivery, smoking during
pregnancy, number of previous deliveries, and mode of delivery is from 1987 onwards
(maternal socioeconomic status from 1991 onwards)
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Table 2. Observed transitions from disease/healthy states by 4 years of age to disease state at
the age of 4 to 16 years.
Prior disease state
by age 4 years
Subsequent disease state at age 4 to 16 years
Disease state n (%)
Asthma
(n = 36 162)
Type 1 diabetes 219 (0.6)
No change 35 943 (99.4)
Healthy
(n = 1 672 974a)
Type 1 diabetes 6807 (0.4)
Asthma 44 928 (2.7)
Asthma and type 1 diabetes 271 (<0.1)




No change 2132 (98.3)
Both asthma and type 1 diabetes
(n = 76)
No change 76 (100.0)
a As the size of the initial cohort was not available, but the subcohort sampling fraction was
10%, the denominator in status "Healthy" was estimated by multiplying the subcohort size by
10.
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Supplementary Table 1. Age-, birth decade- and sex-specific, multistate model-based
annual incidences of type 1 diabetes according to prior asthma diagnosis















    1980s 29.7 (28.0–31.4) 41.7 (37.2–46.3)  26. (24.6–27.7) 36.8 (32.6–40.9)
    1990s 38.6 (36.5–40.6) 54.2 (48.5–59.9)  34. (32.1–35.8) 47.7 (42.6–52.9)
    2000s 40.8 (38.2–43.4) 57.3 (51.0–63.7)  35. (33.6–38.2) 50.5 (44.8–56.2)
4–7.9 years
    1980s 44.8 (42.5–47.1) 62.9 (56.4–69.5)  39. (37.4–41.6) 55.5 (49.5–61.4)
    1990s 58.1 (55.4–60.9) 81.7 (73.6–89.8)  51. (48.7–53.7) 72.0 (64.6–79.3)
    2000s 61.5 (57.5–65.6) 86.4 (77.0–95.9)  54. (50.6–57.8) 76.2 (67.6–84.7)
8–11.9
    1980s 51.3 (48.7–53.8) 72.0 (64.7–79.4)  45. (42.8–47.5) 63.5 (56.8–70.1)
    1990s 66.5 (63.4–69.7) 93.5 (84.4–102.6)  58. (55.8–61.5) 82.4 (74.1–90.6)
    2000s - a - - -  - - - -
12–16
    1980s 42.4 (40.1–44.8) 59.6 (53.4–65.8)  37. (35.2–39.6) 52.6 (46.9–58.2)
    1990s 55.1 (51.9–58.3) 77.4 (69.5–85.3)  48. (45.7–51.4) 68.2 (61.1–75.3)
    2000s - a - - -  - - - -
a Annual incidences for age groups 8–11.9 and 12 –16 years for children born in 2000s could
not be estimated due to the end of follow-up by December 31, 2009.
23
Supplementary Table 2. Age-, birth decade- and sex-specific, multistate model-based
annual incidences of asthma according to prior type 1 diabetes diagnosis













    1980s 485. (476.3–494.5) 397. (326.7–468.0)  306. (300.6–312.9) 251. (206.5–295.6)
    1990s 808. (794.6–821.4) 661. (544.4–778.9)  510. (501.8–520.1) 418. (344.3–492.2)
    2000s 749. (734.6–764.0) 613. (504.5–722.5)  473. (463.7–483.8) 387. (319.0–456.6)
4–7.9 years
    1980s 390. (382.3–397.6) 319. (262.5–375.9)  246. (241.2–251.6) 201. (165.9–237.4)
    1990s 649. (637.9–660.8) 531. (437.5–625.8)  410. (402.7–418.2) 336. (276.6–395.4)
    2000s 602. (588.5–615.7) 492. (405.3–580.6)  380. (371.5–389.6) 311. (256.2–366.8)
8–11.9
    1980s 297. (290.7–303.6) 243. (200.0–286.5)  187. (183.4–192.0) 153. (126.4–180.9)
    1990s 494. (485.0–504.9) 405. (333.3–477.0)  312. (306.1–319.4) 256. (210.7–301.3)
    2000s - a - - -  - - - -
12–16 years
    1980s 171. (166.2–175.9) 140. (115.0–165.0)  108. (104.9–111.2) 88.4 (72.7–104.2)
    1990s 285. (277.0–293.1) 233. (191.7–274.9)  180. (174.9–185.3) 147. (121.2–173.6)
    2000s - a - - -  - - - -
a Annual incidences for age groups 8–11.9 and 12 –16 years for children born in 2000s could
not be estimated due to the end of follow-up by December 31, 2009.
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Supplementary Table 3. Results from sensitivity analyses using different approaches in






Models that account for maternal








HR HR HR HR
Type 1 diabetes
(Asthma)
1.41 1.37 1.45 1.37
Asthma
(Type 1 diabetes)
0.82 0.86 0.90 0.82
a variables obtained from the Medical Birth Register
b an analysis that was based on a multiple imputation scheme of fully conditional specification
including all relevant variables, and implemented in SAS PROC MI and MIANALYZE
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Supplementary Table 4. The associations between asthma and type 1 diabetes -
comparison of unadjusted hazard ratios from the multistate and the crude case-cohort







































a The most appropriate models to the left, crudeness increases to the right
b Unadjusted multistate model reported in the paper. The follow-up from birth up to 31 Dec
2008 is decomposed into distinct time intervals carefully defined by the observed state
transitions, and age is incorporated by the piecewise exponential model.
c A Cox model where both the order of the diagnoses and age were crudely taken into account
as well as the case-cohort design and the stratified subcohort sampling (Cox 3: follow-up time
starting from age of 3 years, exposure disease occurring before age of 3 years no vs. yes). We
used the SAS macros written by and described in Langholz and Jiao. Computational methods
for case-cohort studies. Comput Stat & Data Anal 2007;51:3737-48.
d A Cox model where both the order of the diagnoses and age were crudely taken into account
using different cut off point than in Cox 3 (Cox 2: follow-up time starting from age of 6 years,
exposure disease occurring before age of 6 years no vs. yes).
e A Cox model where the sequential order of the diagnoses was taken crudely into account,
but not the age (Cox 1: follow-up time since birth, exposure disease no vs. yes occurring prior
to the index disease)
f A Cox model where neither the sequential order of the disease diagnoses nor the age were
taken into account in any way (Cox 0: follow-up time since birth, exposure disease no vs. yes
(occurring at any time).
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Figure 1. The final multistate transition model, where λ1(t) and λ2(t) are the piecewise constant
baseline transition rates, βd and βa consist of the log hazard ratios for factors sex and birth
decade contained in x, both for type 1 diabetes and asthma, respectively. Parameters ξ and θ
represent the change in the transition rate (log hazard ratios) due to prior appearance of the
other disease.
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Figure 2. Frequency of children with only asthma (green), only type 1 diabetes (blue), and
both asthma and type 1 diabetes (black) by age and birth decade.
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Figure 3. The association of prior asthma/type 1 diabetes, sex and birth decade with type 1
diabetes (black dots) and asthma (white dots). Data points are hazard ratios (HR) with 95%
confidence intervals (bars) converted from the final multistate model, no prior asthma/type 1
diabetes, female sex and birth decade 1980s as the reference categories.
